US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Context Therapeutics Inc.

1.40

0.0000

Post-market: 1.31-0.0900-6.43%17:28 EDT

Volume:932.38K

Turnover:1.35M

Market Cap:125.59M

PE:-3.61

High:1.55

Open:1.47

Low:1.35

Close:1.40

52wk High:2.59

52wk Low:0.4900

Shares:89.70M

Float Shares:37.70M

Volume Ratio:1.68

T/O Rate:2.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3875

EPS(LYR):-0.4575

ROE:-37.25%

ROA:-25.22%

PB:1.52

PE(LYR):-3.06

Loading ...

Overview Company News Filings

Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025

BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule

Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule

Context Therapeutics Gains 11%, Insider Trades Reap Benefit

Simply Wall St.

Context Therapeutics initiated with a Buy at Guggenheim

Context Therapeutics Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Context Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $4 From $5

THOMSON REUTERS

Context Therapeutics Q2 net loss widens, cash funds ops into 2027

Context Therapeutics Inc - Expects Its Cash and Cash Equivalents Will Continue to Fund Operations Into 2027

THOMSON REUTERS

Context Therapeutics Inc. Q2 Basic EPS USD -0.09

THOMSON REUTERS

Context Therapeutics Inc. Conducted Annual Stockholders Meeting

Alex C. Levit, Chief Legal Officer, Reports Acquisition of Common Shares in Context Therapeutics Inc

CFO Jennifer Lynn Minai-Azary Acquires Common Shares of Context Therapeutics Inc

Context Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Karen Deborah Chagin

Context Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting

Context Therapeutics Appoints Dr. Karen Chagin as Chief Medical Officer, Effective June 9, 2025

Context Therapeutics Inc. Announces New Stock Option Awards to Induce Employment

Press Release: Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

Press Release: Context Therapeutics Announces Chief Medical Officer Transition

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CNTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNTX\",,,,,undefined,":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":1.4,"timestamp":1760126400000,"preClose":1.4,"halted":0,"volume":932378,"hourTrading":{"tag":"盘后","latestPrice":1.31,"preClose":1.4,"latestTime":"17:28 EDT","volume":14377,"amount":18909.991901899997,"timestamp":1760131738657},"delay":0,"floatShares":37696393,"shares":89704194,"eps":-0.387496,"marketStatus":"Post-Mkt","change":0,"latestTime":"10-10 17:34:20 EDT","open":1.47,"high":1.55,"low":1.35,"amount":1352829.4769234,"amplitude":0.142857,"askPrice":1.47,"askSize":14,"bidPrice":1.31,"bidSize":1162,"shortable":3,"etf":0,"ttmEps":-0.387496,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1760140800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":1.4,"preHourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.4,"latestTime":"09:29 EDT","volume":33743,"amount":49050.8898716,"timestamp":1760102960063},"postHourTrading":{"tag":"盘后","latestPrice":1.31,"preClose":1.4,"latestTime":"17:28 EDT","volume":14377,"amount":18909.991901899997,"timestamp":1760131738657},"volumeRatio":1.677902},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNTX\",,,,,undefined,":{"symbol":"CNTX","floatShares":37696393,"roa":"-25.22%","roe":"-37.25%","lyrEps":-0.457495,"volumeRatio":1.677902,"shares":89704194,"dividePrice":0,"high":1.55,"amplitude":0.142857,"preClose":1.4,"low":1.35,"week52Low":0.49,"pbRate":"1.52","week52High":2.5899,"institutionHeld":0,"latestPrice":1.4,"committee":0.97619,"eps":-0.387496,"divideRate":0,"volume":932378,"delay":0,"ttmEps":-0.387496,"open":1.47,"prevYearClose":1.05,"prevWeekClose":1.1,"prevMonthClose":0.9688,"prevQuarterClose":0.9688,"fiveDayClose":1.1,"twentyDayClose":0.835,"sixtyDayClose":0.9119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-06","symbol":"CNTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.09},{"market":"US","date":"2025-05-07","symbol":"CNTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1758168000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNTX","date":"2025-10-09","current":-3.638747,"percent":0.268795,"low":-12.262263,"twenty":-3.951078,"median":-2.210319,"eighty":-0.877124,"high":18.148289,"avg":-2.689565,"sd":3.144443,"marketCap":102262781},"quantilePoints":[{"date":"2021-07-29","current":17.91077,"twenty":17.91077,"median":17.91077,"eighty":17.91077,"marketCap":88227308},{"date":"2021-08-05","current":18.148289,"twenty":17.91077,"median":18.029529,"eighty":18.148289,"marketCap":89397308},{"date":"2021-10-22","current":-10.102458,"twenty":-6.812632,"median":17.91077,"eighty":18.148289,"marketCap":76608946},{"date":"2021-10-29","current":-8.324772,"twenty":-9.37404,"median":-6.73185,"eighty":18.053281,"marketCap":63128401},{"date":"2021-11-05","current":-7.956227,"twenty":-8.79015,"median":-7.89119,"eighty":17.91077,"marketCap":60333654},{"date":"2021-11-12","current":-7.818926,"twenty":-8.567578,"median":-7.923709,"eighty":17.91077,"marketCap":59292474},{"date":"2021-11-19","current":-7.067384,"twenty":-8.414378,"median":-7.558777,"eighty":17.91077,"marketCap":53593382},{"date":"2021-11-26","current":-7.370892,"twenty":-8.347896,"median":-7.486514,"eighty":13.042323,"marketCap":55894939},{"date":"2021-12-03","current":-7.130156,"twenty":-8.434612,"median":-7.544325,"eighty":-6.491541,"marketCap":58109019},{"date":"2021-12-10","current":-10.538494,"twenty":-9.837551,"median":-7.818926,"eighty":-6.73185,"marketCap":85886137},{"date":"2021-12-17","current":-5.817719,"twenty":-9.53591,"median":-7.633709,"eighty":-6.469339,"marketCap":47412979},{"date":"2021-12-23","current":-6.307426,"twenty":-8.888428,"median":-7.508193,"eighty":-6.209485,"marketCap":51403970},{"date":"2021-12-31","current":-5.210482,"twenty":-8.642732,"median":-7.228075,"eighty":-5.680601,"marketCap":42464149},{"date":"2022-01-07","current":-4.955835,"twenty":-8.454846,"median":-7.113223,"eighty":-5.367189,"marketCap":40388833},{"date":"2022-01-14","current":-4.407363,"twenty":-8.353677,"median":-7.067384,"eighty":-4.995011,"marketCap":35918923},{"date":"2022-01-21","current":-4.113539,"twenty":-8.330553,"median":-6.866487,"eighty":-4.850058,"marketCap":33524328},{"date":"2022-01-28","current":-3.800126,"twenty":-8.310637,"median":-6.676344,"eighty":-4.403445,"marketCap":30970094},{"date":"2022-02-04","current":-4.368186,"twenty":-8.164729,"median":-6.346602,"eighty":-4.321174,"marketCap":35599644},{"date":"2022-02-11","current":-3.839303,"twenty":-8.10065,"median":-6.170308,"eighty":-4.129209,"marketCap":31289373},{"date":"2022-02-18","current":-3.76095,"twenty":-8.081966,"median":-5.817719,"eighty":-4.031267,"marketCap":30650814},{"date":"2022-02-25","current":-3.506302,"twenty":-8.070404,"median":-5.523895,"eighty":-3.937244,"marketCap":28575499},{"date":"2022-03-04","current":-3.741361,"twenty":-7.999585,"median":-5.406365,"eighty":-3.831467,"marketCap":30491175},{"date":"2022-03-11","current":-3.565067,"twenty":-7.956227,"median":-5.210482,"eighty":-3.800126,"marketCap":29054418},{"date":"2022-03-18","current":-4.113539,"twenty":-7.917205,"median":-4.985217,"eighty":-3.753114,"marketCap":33524328},{"date":"2022-03-25","current":-3.435408,"twenty":-7.847832,"median":-4.877482,"eighty":-3.682597,"marketCap":35923619},{"date":"2022-04-01","current":-3.664436,"twenty":-7.752755,"median":-4.642423,"eighty":-3.655173,"marketCap":38318527},{"date":"2022-04-08","current":-3.878194,"twenty":-7.618723,"median":-4.466128,"eighty":-3.663865,"marketCap":40553774},{"date":"2022-04-14","current":-2.748327,"twenty":-7.547215,"median":-4.387775,"eighty":-3.553314,"marketCap":28738895},{"date":"2022-04-22","current":-2.473494,"twenty":-7.512529,"median":-4.289833,"eighty":-3.506302,"marketCap":25865005},{"date":"2022-04-29","current":-2.21393,"twenty":-7.440265,"median":-4.191892,"eighty":-3.433942,"marketCap":23150776},{"date":"2022-05-06","current":-2.244467,"twenty":-7.313765,"median":-4.113539,"eighty":-3.331713,"marketCap":23470097},{"date":"2022-05-13","current":-1.780396,"twenty":-7.204267,"median":-4.113539,"eighty":-3.018579,"marketCap":23150776},{"date":"2022-05-20","current":-2.173312,"twenty":-7.153195,"median":-4.050461,"eighty":-2.580373,"marketCap":28259913},{"date":"2022-05-27","current":-2.517112,"twenty":-7.11661,"median":-4.015597,"eighty":-2.476207,"marketCap":32730408},{"date":"2022-06-03","current":-2.455719,"twenty":-7.093399,"median":-3.985074,"eighty":-2.47485,"marketCap":31932106},{"date":"2022-06-10","current":-2.345212,"twenty":-7.078946,"median":-3.937244,"eighty":-2.433295,"marketCap":30495161},{"date":"2022-06-17","current":-2.639898,"twenty":-7.04715,"median":-3.858891,"eighty":-2.430839,"marketCap":34327013},{"date":"2022-06-24","current":-2.578505,"twenty":-6.966215,"median":-3.839303,"eighty":-2.443441,"marketCap":33528711},{"date":"2022-07-01","current":-2.529391,"twenty":-6.866487,"median":-3.819714,"eighty":-2.455719,"marketCap":32890069},{"date":"2022-07-08","current":-2.517112,"twenty":-6.758777,"median":-3.800126,"eighty":-2.443441,"marketCap":32730408},{"date":"2022-07-15","current":-2.406605,"twenty":-6.73185,"median":-3.76095,"eighty":-2.406605,"marketCap":31293463},{"date":"2022-07-22","current":-2.406605,"twenty":-6.64304,"median":-3.682597,"eighty":-2.404149,"marketCap":31293463},{"date":"2022-07-29","current":-2.320532,"twenty":-6.469339,"median":-3.664436,"eighty":-2.369769,"marketCap":30174243},{"date":"2022-08-05","current":-2.35749,"twenty":-6.363574,"median":-3.604243,"eighty":-2.35749,"marketCap":30654821},{"date":"2022-08-12","current":-2.616619,"twenty":-6.315261,"median":-3.545479,"eighty":-2.35749,"marketCap":31293463},{"date":"2022-08-19","current":-2.443067,"twenty":-6.229073,"median":-3.506302,"eighty":-2.35749,"marketCap":29217876},{"date":"2022-08-26","current":-2.563218,"twenty":-6.146802,"median":-3.465945,"eighty":-2.367313,"marketCap":30654821},{"date":"2022-09-02","current":-2.509818,"twenty":-6.115461,"median":-3.420663,"eighty":-2.369769,"marketCap":30016179},{"date":"2022-09-09","current":-2.429717,"twenty":-5.935249,"median":-3.364287,"eighty":-2.369769,"marketCap":29058216},{"date":"2022-09-16","current":-1.935764,"twenty":-5.735448,"median":-3.297992,"eighty":-2.35749,"marketCap":23150776},{"date":"2022-09-23","current":-1.628712,"twenty":-5.586577,"median":-3.019342,"eighty":-2.345212,"marketCap":19478584},{"date":"2022-09-30","current":-1.48186,"twenty":-5.523895,"median":-2.873192,"eighty":-2.332933,"marketCap":17722318},{"date":"2022-10-07","current":-1.548611,"twenty":-5.476883,"median":-2.756545,"eighty":-2.310806,"marketCap":18520621},{"date":"2022-10-14","current":-1.45516,"twenty":-5.39853,"median":-2.738127,"eighty":-2.27154,"marketCap":17402997},{"date":"2022-10-21","current":-1.40176,"twenty":-5.367189,"median":-2.70568,"eighty":-2.223091,"marketCap":16764355},{"date":"2022-10-28","current":-1.682112,"twenty":-5.273165,"median":-2.676734,"eighty":-2.198661,"marketCap":20117226},{"date":"2022-11-04","current":-1.561961,"twenty":-5.092952,"median":-2.639898,"eighty":-2.080175,"marketCap":18680282},{"date":"2022-11-11","current":-1.366517,"twenty":-5.002846,"median":-2.623294,"eighty":-2.004621,"marketCap":19638245},{"date":"2022-11-18","current":-1.377627,"twenty":-4.983258,"median":-2.61598,"eighty":-1.849366,"marketCap":19797905},{"date":"2022-11-25","current":-1.522055,"twenty":-4.967588,"median":-2.591717,"eighty":-1.771096,"marketCap":21873492},{"date":"2022-12-02","current":-1.533165,"twenty":-4.924494,"median":-2.578505,"eighty":-1.687046,"marketCap":22033153},{"date":"2022-12-09","current":-0.92201,"twenty":-4.822635,"median":-2.563218,"eighty":-1.644732,"marketCap":13250227},{"date":"2022-12-16","current":-0.821799,"twenty":-4.716858,"median":-2.549868,"eighty":-1.594001,"marketCap":11810089},{"date":"2022-12-23","current":-0.699923,"twenty":-4.650258,"median":-2.532954,"eighty":-1.566974,"marketCap":10058613},{"date":"2022-12-30","current":-0.724032,"twenty":-4.599328,"median":-2.52628,"eighty":-1.5567,"marketCap":10405076},{"date":"2023-01-06","current":-0.866572,"twenty":-4.583657,"median":-2.52014,"eighty":-1.544275,"marketCap":12453521},{"date":"2023-01-13","current":-0.814355,"twenty":-4.466128,"median":-2.509818,"eighty":-1.533165,"marketCap":11703116},{"date":"2023-01-20","current":-0.770471,"twenty":-4.419116,"median":-2.496468,"eighty":-1.519241,"marketCap":11072457},{"date":"2023-01-27","current":-0.777693,"twenty":-4.391693,"median":-2.473494,"eighty":-1.48186,"marketCap":11176237},{"date":"2023-02-03","current":-1.013222,"twenty":-4.372104,"median":-2.455719,"eighty":-1.464106,"marketCap":14561040},{"date":"2023-02-10","current":-0.944341,"twenty":-4.352516,"median":-2.455719,"eighty":-1.42846,"marketCap":13571145},{"date":"2023-02-17","current":-0.919455,"twenty":-4.254574,"median":-2.443441,"eighty":-1.410452,"marketCap":13213505},{"date":"2023-02-24","current":-0.855684,"twenty":-4.219315,"median":-2.443067,"eighty":-1.384097,"marketCap":12297054},{"date":"2023-03-03","current":-0.844352,"twenty":-4.199727,"median":-2.428703,"eighty":-1.333187,"marketCap":12134200},{"date":"2023-03-10","current":-0.76636,"twenty":-4.156633,"median":-2.406605,"eighty":-1.284304,"marketCap":11013383},{"date":"2023-03-17","current":-0.687147,"twenty":-4.121374,"median":-2.404811,"eighty":-1.103212,"marketCap":9875003},{"date":"2023-03-24","current":-0.667228,"twenty":-4.113539,"median":-2.394326,"eighty":-1.018621,"marketCap":9898952},{"date":"2023-03-31","current":-0.605025,"twenty":-4.113539,"median":-2.375908,"eighty":-0.939008,"marketCap":8976114},{"date":"2023-04-06","current":-0.641077,"twenty":-4.113539,"median":-2.369769,"eighty":-0.925499,"marketCap":9510977},{"date":"2023-04-14","current":-0.634943,"twenty":-4.09269,"median":-2.35749,"eighty":-0.904345,"marketCap":9419971},{"date":"2023-04-21","current":-0.661955,"twenty":-4.058759,"median":-2.351351,"eighty":-0.873505,"marketCap":9820719},{"date":"2023-04-28","current":-0.624289,"twenty":-4.051324,"median":-2.345212,"eighty":-0.859195,"marketCap":9261907},{"date":"2023-05-05","current":-0.518716,"twenty":-4.041763,"median":-2.332933,"eighty":-0.846685,"marketCap":7695637},{"date":"2023-05-12","current":-0.523457,"twenty":-4.02735,"median":-2.320655,"eighty":-0.844352,"marketCap":9268293},{"date":"2023-05-19","current":-0.504972,"twenty":-4.007762,"median":-2.28561,"eighty":-0.821977,"marketCap":8940989},{"date":"2023-05-26","current":-0.757458,"twenty":-3.991635,"median":-2.27154,"eighty":-0.808066,"marketCap":13411484},{"date":"2023-06-02","current":-0.955839,"twenty":-3.978967,"median":-2.27154,"eighty":-0.8074,"marketCap":16924016},{"date":"2023-06-09","current":-1.181273,"twenty":-3.951078,"median":-2.221564,"eighty":-0.807822,"marketCap":20915529},{"date":"2023-06-16","current":-1.100117,"twenty":-3.937244,"median":-2.206296,"eighty":-0.809267,"marketCap":19478584},{"date":"2023-06-23","current":-1.199308,"twenty":-3.937244,"median":-2.198661,"eighty":-0.810666,"marketCap":21234850},{"date":"2023-06-30","current":-1.253412,"twenty":-3.913624,"median":-2.173312,"eighty":-0.812422,"marketCap":22192813},{"date":"2023-07-06","current":-1.352603,"twenty":-3.890004,"median":-2.162715,"eighty":-0.813711,"marketCap":23949079},{"date":"2023-07-14","current":-1.109134,"twenty":-3.870473,"median":-2.079565,"eighty":-0.817333,"marketCap":19638245},{"date":"2023-07-21","current":-1.073065,"twenty":-3.866612,"median":-2.076514,"eighty":-0.818821,"marketCap":18999603},{"date":"2023-07-28","current":-1.000926,"twenty":-3.858891,"median":-2.056665,"eighty":-0.822065,"marketCap":17722318},{"date":"2023-08-04","current":-1.118152,"twenty":-3.847138,"median":-1.909064,"eighty":-0.825476,"marketCap":19797905},{"date":"2023-08-11","current":-0.886495,"twenty":-3.82755,"median":-1.848191,"eighty":-0.825476,"marketCap":16604695},{"date":"2023-08-18","current":-0.860923,"twenty":-3.819714,"median":-1.775563,"eighty":-0.83633,"marketCap":16125713},{"date":"2023-08-25","current":-0.903543,"twenty":-3.819714,"median":-1.739536,"eighty":-0.843463,"marketCap":16924016},{"date":"2023-09-01","current":-0.877971,"twenty":-3.807961,"median":-1.682112,"eighty":-0.844352,"marketCap":16445034},{"date":"2023-09-08","current":-0.788469,"twenty":-3.800126,"median":-1.682112,"eighty":-0.843019,"marketCap":14768599},{"date":"2023-09-15","current":-0.886495,"twenty":-3.784456,"median":-1.622037,"eighty":-0.843019,"marketCap":16604695},{"date":"2023-09-22","current":-0.835351,"twenty":-3.76095,"median":-1.602011,"eighty":-0.824693,"marketCap":15646731},{"date":"2023-09-29","current":-1.082547,"twenty":-3.753114,"median":-1.579625,"eighty":-0.824693,"marketCap":20276887},{"date":"2023-10-06","current":-1.108118,"twenty":-3.717855,"median":-1.561961,"eighty":-0.830719,"marketCap":20755868},{"date":"2023-10-13","current":-1.108118,"twenty":-3.682597,"median":-1.558673,"eighty":-0.837056,"marketCap":20755868},{"date":"2023-10-20","current":-1.074023,"twenty":-3.682597,"median":-1.548611,"eighty":-0.84062,"marketCap":20117226},{"date":"2023-10-27","current":-0.929115,"twenty":-3.682597,"median":-1.544275,"eighty":-0.841627,"marketCap":17402997},{"date":"2023-11-02","current":-0.946163,"twenty":-3.6717,"median":-1.535261,"eighty":-0.843463,"marketCap":17722318},{"date":"2023-11-10","current":-0.924853,"twenty":-3.663579,"median":-1.533165,"eighty":-0.844352,"marketCap":17323167},{"date":"2023-11-17","current":-0.777101,"twenty":-3.651255,"median":-1.521911,"eighty":-0.832263,"marketCap":16125713},{"date":"2023-11-24","current":-0.666384,"twenty":-3.612079,"median":-1.499836,"eighty":-0.821977,"marketCap":13828198},{"date":"2023-12-01","current":-0.653996,"twenty":-3.557232,"median":-1.48186,"eighty":-0.810321,"marketCap":13571145},{"date":"2023-12-08","current":-0.657843,"twenty":-3.545479,"median":-1.46851,"eighty":-0.807444,"marketCap":13650975},{"date":"2023-12-15","current":-0.64661,"twenty":-3.531988,"median":-1.455278,"eighty":-0.796618,"marketCap":13417870},{"date":"2023-12-22","current":-0.861736,"twenty":-3.509571,"median":-1.433759,"eighty":-0.787336,"marketCap":17881979},{"date":"2023-12-29","current":-0.884818,"twenty":-3.506302,"median":-1.42846,"eighty":-0.788469,"marketCap":18360960},{"date":"2024-01-05","current":-0.961759,"twenty":-3.506302,"median":-1.41511,"eighty":-0.790882,"marketCap":19957566},{"date":"2024-01-12","current":-0.900207,"twenty":-3.506302,"median":-1.409696,"eighty":-0.793112,"marketCap":18680282},{"date":"2024-01-19","current":-0.846348,"twenty":-3.490159,"median":-1.395085,"eighty":-0.796618,"marketCap":17562658},{"date":"2024-01-26","current":-0.708086,"twenty":-3.45373,"median":-1.366517,"eighty":-0.790077,"marketCap":14693558},{"date":"2024-02-02","current":-0.79249,"twenty":-3.434431,"median":-1.342895,"eighty":-0.787336,"marketCap":16445034},{"date":"2024-02-09","current":-0.761713,"twenty":-3.423123,"median":-1.325551,"eighty":-0.785065,"marketCap":15806392},{"date":"2024-02-16","current":-0.784795,"twenty":-3.39269,"median":-1.290581,"eighty":-0.785065,"marketCap":16285374},{"date":"2024-02-23","current":-0.900207,"twenty":-3.367225,"median":-1.28238,"eighty":-0.785691,"marketCap":18680282},{"date":"2024-03-01","current":-0.877124,"twenty":-3.350164,"median":-1.253412,"eighty":-0.786958,"marketCap":18201300},{"date":"2024-03-08","current":-0.884818,"twenty":-3.310207,"median":-1.217342,"eighty":-0.789273,"marketCap":18360960},{"date":"2024-03-15","current":-0.854042,"twenty":-3.27967,"median":-1.199308,"eighty":-0.79249,"marketCap":17722318},{"date":"2024-03-22","current":-0.712883,"twenty":-3.169737,"median":-1.179461,"eighty":-0.789273,"marketCap":17083676},{"date":"2024-03-28","current":-0.920752,"twenty":-3.023159,"median":-1.163239,"eighty":-0.788469,"marketCap":22065085},{"date":"2024-04-05","current":-0.852794,"twenty":-3.015525,"median":-1.154221,"eighty":-0.79249,"marketCap":20436547},{"date":"2024-04-12","current":-1.012693,"twenty":-3.007891,"median":-1.1392,"eighty":-0.79249,"marketCap":24268400},{"date":"2024-04-19","current":-0.939406,"twenty":-2.873192,"median":-1.13369,"eighty":-0.79249,"marketCap":22512134},{"date":"2024-04-26","current":-0.919419,"twenty":-2.77682,"median":-1.114571,"eighty":-0.79249,"marketCap":22033153},{"date":"2024-05-03","current":-1.16593,"twenty":-2.762684,"median":-1.109134,"eighty":-0.79249,"marketCap":27940592},{"date":"2024-05-10","current":-1.370207,"twenty":-2.750406,"median":-1.122661,"eighty":-0.793527,"marketCap":29217876},{"date":"2024-05-17","current":-1.347745,"twenty":-2.748327,"median":-1.13369,"eighty":-0.800107,"marketCap":28738895},{"date":"2024-05-24","current":-6.858415,"twenty":-2.762684,"median":-1.144078,"eighty":-0.801255,"marketCap":146246708},{"date":"2024-05-31","current":-7.034271,"twenty":-3.009418,"median":-1.15248,"eighty":-0.801255,"marketCap":149996624},{"date":"2024-06-07","current":-6.154988,"twenty":-3.301046,"median":-1.163239,"eighty":-0.803476,"marketCap":131247046},{"date":"2024-06-14","current":-6.928757,"twenty":-3.384855,"median":-1.16593,"eighty":-0.80569,"marketCap":147746674},{"date":"2024-06-21","current":-7.632185,"twenty":-3.45373,"median":-1.181273,"eighty":-0.80702,"marketCap":162746337},{"date":"2024-06-28","current":-7.069443,"twenty":-3.506302,"median":-1.184834,"eighty":-0.807244,"marketCap":150746607},{"date":"2024-07-05","current":-6.295673,"twenty":-3.525242,"median":-1.199308,"eighty":-0.807489,"marketCap":134246978},{"date":"2024-07-12","current":-7.104614,"twenty":-3.651255,"median":-1.207115,"eighty":-0.807758,"marketCap":151496590},{"date":"2024-07-15","current":-7.104614,"twenty":-3.663294,"median":-1.208325,"eighty":-0.807818,"marketCap":151496590},{"date":"2024-08-02","current":-7.843213,"twenty":-3.664436,"median":-1.217342,"eighty":-0.807878,"marketCap":167246235},{"date":"2024-08-09","current":-9.694467,"twenty":-3.741361,"median":-1.253412,"eighty":-0.807878,"marketCap":179995948},{"date":"2024-08-16","current":-10.7447,"twenty":-3.800126,"median":-1.260162,"eighty":-0.807878,"marketCap":199495509},{"date":"2024-08-23","current":-10.098403,"twenty":-3.839303,"median":-1.277638,"eighty":-0.8088,"marketCap":187495780},{"date":"2024-08-30","current":-9.896435,"twenty":-3.937244,"median":-1.287935,"eighty":-0.809779,"marketCap":183745864},{"date":"2024-09-06","current":-9.209743,"twenty":-3.987261,"median":-1.307246,"eighty":-0.810862,"marketCap":170996151},{"date":"2024-09-13","current":-8.684626,"twenty":-4.047873,"median":-1.333187,"eighty":-0.813711,"marketCap":161246370},{"date":"2024-09-20","current":-9.007775,"twenty":-4.113539,"median":-1.350174,"eighty":-0.815329,"marketCap":167246235},{"date":"2024-09-27","current":-7.472818,"twenty":-4.19581,"median":-1.366517,"eighty":-0.815572,"marketCap":138746877},{"date":"2024-10-04","current":-7.997935,"twenty":-4.372104,"median":-1.383018,"eighty":-0.81748,"marketCap":148496657},{"date":"2024-10-11","current":-6.907307,"twenty":-4.587575,"median":-1.40176,"eighty":-0.821031,"marketCap":128247113},{"date":"2024-10-18","current":-8.119116,"twenty":-4.893153,"median":-1.410956,"eighty":-0.822154,"marketCap":150746607},{"date":"2024-10-25","current":-9.492498,"twenty":-5.053776,"median":-1.42846,"eighty":-0.822637,"marketCap":176246033},{"date":"2024-10-31","current":-8.765414,"twenty":-5.39853,"median":-1.433759,"eighty":-0.824781,"marketCap":162746337},{"date":"2024-11-08","current":-5.198529,"twenty":-5.586577,"median":-1.455278,"eighty":-0.826726,"marketCap":156746472},{"date":"2024-11-15","current":-4.725935,"twenty":-5.523895,"median":-1.46851,"eighty":-0.827424,"marketCap":142496792},{"date":"2024-11-22","current":-3.731002,"twenty":-5.476883,"median":-1.48186,"eighty":-0.829628,"marketCap":112497468},{"date":"2024-11-29","current":-3.780748,"twenty":-5.414201,"median":-1.492609,"eighty":-0.832716,"marketCap":113997434},{"date":"2024-12-06","current":-3.731002,"twenty":-5.367189,"median":-1.499836,"eighty":-0.836672,"marketCap":112497468},{"date":"2024-12-13","current":-3.581762,"twenty":-5.304506,"median":-1.521983,"eighty":-0.83898,"marketCap":107997569},{"date":"2024-12-20","current":-2.711195,"twenty":-5.205701,"median":-1.533165,"eighty":-0.839527,"marketCap":81748160},{"date":"2024-12-27","current":-2.835561,"twenty":-5.17863,"median":-1.535261,"eighty":-0.840116,"marketCap":85498075},{"date":"2025-01-03","current":-2.959928,"twenty":-5.099036,"median":-1.544275,"eighty":-0.84213,"marketCap":89247991},{"date":"2025-01-10","current":-3.009675,"twenty":-5.079137,"median":-1.548611,"eighty":-0.843908,"marketCap":90747957},{"date":"2025-01-17","current":-2.433608,"twenty":-5.026512,"median":-1.561961,"eighty":-0.844352,"marketCap":73378348},{"date":"2025-01-24","current":-2.259495,"twenty":-5.002846,"median":-1.568227,"eighty":-0.844352,"marketCap":68128466},{"date":"2025-01-31","current":-2.845048,"twenty":-4.983258,"median":-1.583939,"eighty":-0.844352,"marketCap":85784120},{"date":"2025-02-07","current":-2.666247,"twenty":-4.96367,"median":-1.608687,"eighty":-0.845218,"marketCap":80392898},{"date":"2025-02-14","current":-2.397897,"twenty":-4.922363,"median":-1.628712,"eighty":-0.845998,"marketCap":72301580},{"date":"2025-02-21","current":-2.350296,"twenty":-4.891022,"median":-1.682112,"eighty":-0.846132,"marketCap":70866313},{"date":"2025-02-28","current":-2.410095,"twenty":-4.86661,"median":-1.688279,"eighty":-0.846218,"marketCap":72669367},{"date":"2025-03-07","current":-2.472273,"twenty":-4.806327,"median":-1.743561,"eighty":-0.846348,"marketCap":74544185},{"date":"2025-03-14","current":-1.944498,"twenty":-4.734592,"median":-1.77798,"eighty":-0.846348,"marketCap":58630661},{"date":"2025-03-21","current":-2.29139,"twenty":-4.708201,"median":-1.854068,"eighty":-0.847016,"marketCap":69090170},{"date":"2025-03-28","current":-2.4721,"twenty":-4.650258,"median":-1.922414,"eighty":-0.848862,"marketCap":66067138},{"date":"2025-04-04","current":-2.413361,"twenty":-4.59541,"median":-1.944498,"eighty":-0.851037,"marketCap":64497315},{"date":"2025-04-11","current":-2.280106,"twenty":-4.580872,"median":-2.04062,"eighty":-0.852399,"marketCap":60936058},{"date":"2025-04-17","current":-2.903753,"twenty":-4.554582,"median":-2.0535,"eighty":-0.852478,"marketCap":77603098},{"date":"2025-04-25","current":-3.356552,"twenty":-4.454375,"median":-2.076514,"eighty":-0.853044,"marketCap":89704194},{"date":"2025-05-02","current":-2.895026,"twenty":-4.403445,"median":-2.091503,"eighty":-0.854326,"marketCap":77369867},{"date":"2025-05-09","current":-2.509874,"twenty":-4.383857,"median":-2.162715,"eighty":-0.855506,"marketCap":69359282},{"date":"2025-05-16","current":-2.434565,"twenty":-4.364268,"median":-2.198661,"eighty":-0.855879,"marketCap":67278145},{"date":"2025-05-23","current":-2.289789,"twenty":-4.325092,"median":-2.203443,"eighty":-0.857513,"marketCap":63277338},{"date":"2025-05-30","current":-2.003484,"twenty":-4.231068,"median":-2.203443,"eighty":-0.860923,"marketCap":55365428},{"date":"2025-06-06","current":-1.790541,"twenty":-4.21148,"median":-2.198661,"eighty":-0.860923,"marketCap":49480833},{"date":"2025-06-13","current":-2.118396,"twenty":-4.191892,"median":-2.173312,"eighty":-0.861736,"marketCap":58540957},{"date":"2025-06-20","current":-1.829819,"twenty":-4.181356,"median":-2.162715,"eighty":-0.861736,"marketCap":50566254},{"date":"2025-06-27","current":-2.114176,"twenty":-4.142246,"median":-2.121967,"eighty":-0.863916,"marketCap":58424341},{"date":"2025-07-03","current":-2.078144,"twenty":-4.121374,"median":-2.121967,"eighty":-0.865456,"marketCap":57428624},{"date":"2025-07-11","current":-2.175202,"twenty":-4.113539,"median":-2.114176,"eighty":-0.866119,"marketCap":60110780},{"date":"2025-07-18","current":-2.960106,"twenty":-4.113539,"median":-2.126187,"eighty":-0.866391,"marketCap":81801254},{"date":"2025-07-25","current":-2.729309,"twenty":-4.113539,"median":-2.155726,"eighty":-0.868172,"marketCap":75423286},{"date":"2025-08-01","current":-2.369643,"twenty":-4.107877,"median":-2.17166,"eighty":-0.869363,"marketCap":65484061},{"date":"2025-08-08","current":-1.833022,"twenty":-4.07849,"median":-2.175202,"eighty":-0.869447,"marketCap":62703231},{"date":"2025-08-15","current":-1.930836,"twenty":-4.057431,"median":-2.166362,"eighty":-0.869483,"marketCap":66049198},{"date":"2025-08-22","current":-2.307667,"twenty":-4.054523,"median":-2.173312,"eighty":-0.869746,"marketCap":78939690},{"date":"2025-08-29","current":-2.234766,"twenty":-4.049431,"median":-2.186932,"eighty":-0.871631,"marketCap":76445914},{"date":"2025-09-05","current":-2.171567,"twenty":-4.041763,"median":-2.198661,"eighty":-0.873971,"marketCap":74284043},{"date":"2025-09-12","current":-2.192284,"twenty":-4.02735,"median":-2.198661,"eighty":-0.876303,"marketCap":74992706},{"date":"2025-09-19","current":-2.622349,"twenty":-4.007762,"median":-2.198661,"eighty":-0.877124,"marketCap":89704194},{"date":"2025-09-26","current":-2.368243,"twenty":-3.991635,"median":-2.202773,"eighty":-0.877124,"marketCap":81011857},{"date":"2025-10-03","current":-2.621562,"twenty":-3.972859,"median":-2.206818,"eighty":-0.877124,"marketCap":89677282},{"date":"2025-10-09","current":-2.989478,"twenty":-3.951078,"median":-2.210319,"eighty":-0.877124,"marketCap":102262781}],"updateTime":1760117274279},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2573671135","title":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671135","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671135?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:30","pubTimestamp":1759750258,"startTime":"0","endTime":"0","summary":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025. Context Therapeutics Inc. has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's  40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a \"Trial in Progress\" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager  for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL18BYyK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","BK4007","BK4112","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","CNTX","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ","BK4588"],"gpt_icon":0},{"id":"2572636186","title":"BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636186?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:25","pubTimestamp":1759526744,"startTime":"0","endTime":"0","summary":"BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule Oct 3 (Reuters) - Context Therapeutics Inc CNTX.O:CONTEXT THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING R","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nTUABLVCPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2572639633","title":"Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2572639633","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572639633?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:15","pubTimestamp":1759522556,"startTime":"0","endTime":"0","summary":"Philadelphia-based Context Therapeutics Inc.  announced on October 3, 2025, the grant of non-qualified stock options to a new employee. The award allows the employee to purchase 30,000 shares of Context's common stock at an exercise price of $0.97 per share, which reflects the closing price on the grant date. The stock options have a 10-year term and will vest over four years: one-fourth will vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 0","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL9f3Fh1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","CNTX","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4007","NDAQ","BK4112"],"gpt_icon":0},{"id":"2572507992","title":"Context Therapeutics Gains 11%, Insider Trades Reap Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2572507992","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572507992?lang=en_us&edition=fundamental","pubTime":"2025-10-03 18:16","pubTimestamp":1759486602,"startTime":"0","endTime":"0","summary":"Last week, Context Therapeutics Inc. ( NASDAQ:CNTX ) insiders, who had purchased shares in the previous 12 months were...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntx/context-therapeutics/news/context-therapeutics-gains-11-insider-trades-reap-benefit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntx/context-therapeutics/news/context-therapeutics-gains-11-insider-trades-reap-benefit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CNTX","BK4139","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2568127914","title":"Context Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2568127914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568127914?lang=en_us&edition=fundamental","pubTime":"2025-09-18 04:40","pubTimestamp":1758141612,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $5 price target The firm’s investment thesis on the stock is cen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNTX","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2564801512","title":"Context Therapeutics Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801512","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564801512?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:32","pubTimestamp":1756812744,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc. has announced that it received an extension from The Nasdaq Stock Market LLC, granting the company an additional 180 days, until February 23, 2026, to comply with the Nasdaq Listing Rule 5550, which requires a minimum bid price of $1.00 per share. This extension follows a previous notice in February 2025, indicating that the company's stock had failed to meet the minimum closing bid price for 30 consecutive business days. Context Therapeutics plans to actively monitor its stock price and may consider options such as a reverse stock split to regain compliance. However, there is no guarantee that the company will meet the requirement by the new deadline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDLbh7QJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2557556119","title":"Context Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $4 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2557556119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557556119?lang=en_us&edition=fundamental","pubTime":"2025-08-07 18:06","pubTimestamp":1754561185,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nAZN4BVWKA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2557881635","title":"Context Therapeutics Q2 net loss widens, cash funds ops into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2557881635","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557881635?lang=en_us&edition=fundamental","pubTime":"2025-08-07 05:39","pubTimestamp":1754516357,"startTime":"0","endTime":"0","summary":"Context Therapeutics Q2 net loss widens, cash funds ops into 2027OverviewContext Q2 net loss widens to $8.8 mln from $2.3 mln last yearOutlookCash and cash equivalents total $83.5 mln, funding operati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLX025DF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2557968307","title":"Context Therapeutics Inc - Expects Its Cash and Cash Equivalents Will Continue to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2557968307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557968307?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:11","pubTimestamp":1754511061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLX025DF9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2557302988","title":"Context Therapeutics Inc. Q2 Basic EPS USD -0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2557302988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557302988?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:11","pubTimestamp":1754511061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLX025DF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2543754069","title":"Context Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543754069","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543754069?lang=en_us&edition=fundamental","pubTime":"2025-06-13 05:15","pubTimestamp":1749762915,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. At the meeting, stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the year ending December 31, 2025. Additionally, stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding common stock at a ratio ranging from 1-for-5 to 1-for-50, as determined by the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Secu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL2rgtdT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2542328650","title":"Alex C. Levit, Chief Legal Officer, Reports Acquisition of Common Shares in Context Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2542328650","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542328650?lang=en_us&edition=fundamental","pubTime":"2025-06-11 05:24","pubTimestamp":1749590663,"startTime":"0","endTime":"0","summary":"Alex C. Levit, Chief Legal Officer and Corporate Secretary, reported an acquisition of common shares of Context Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL5l4qdD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alex C. Levit, Chief Legal Officer, Reports Acquisition of Common Shares in Context Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2542232850","title":"CFO Jennifer Lynn Minai-Azary Acquires Common Shares of Context Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2542232850","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542232850?lang=en_us&edition=fundamental","pubTime":"2025-06-11 05:22","pubTimestamp":1749590564,"startTime":"0","endTime":"0","summary":"Jennifer Lynn Minai-Azary, the Chief Financial Officer of Context Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL8GnL3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2542358321","title":"Context Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Karen Deborah Chagin","url":"https://stock-news.laohu8.com/highlight/detail?id=2542358321","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542358321?lang=en_us&edition=fundamental","pubTime":"2025-06-10 05:14","pubTimestamp":1749503658,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing identifies Karen Deborah Chagin as the beneficial owner, serving as the Chief Medical Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL1lNxRn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2540035767","title":"Context Therapeutics Announces Phase 1 Trial of CTIM-76 for Advanced Solid Tumors at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540035767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540035767?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:30","pubTimestamp":1748863851,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology  Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL2dlCsc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","BK4112","BK4588","BK4007","IE00BKPKM429.USD","CNTX","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585"],"gpt_icon":0},{"id":"2539252214","title":"Context Therapeutics Appoints Dr. Karen Chagin as Chief Medical Officer, Effective June 9, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539252214","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539252214?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:30","pubTimestamp":1748518235,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin, who has extensive experience in T cell therapies for solid tumors, previously held a senior position at Adaptimmune Therapeutics. She succeeds Dr. Karen Smith, who will remain on the company's Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL1f2YFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4007","CNTX","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4588","BK4585","ADAP","IE00BKPKM429.USD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2535257784","title":"Context Therapeutics Inc. Announces New Stock Option Awards to Induce Employment","url":"https://stock-news.laohu8.com/highlight/detail?id=2535257784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535257784?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:38","pubTimestamp":1747082309,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the issuance of non-qualified stock option awards as part of its compensation strategy. On May 12, 2025, the company granted options to purchase a total of 160,000 shares of common stock to two newly hired employees. These options, issued outside of the 2021 Long-Term Performance Incentive Plan, are aligned with Nasdaq Listing Rule 5635. The exercise prices are set at $0.839 and $0.78 per share, corresponding to the closing prices on the respective grant dates of May 5 and May 12, 2025. The stock options come with a 10-year term and a four-year vesting schedule, beginning with one-fourth of the shares vesting after the first year, followed by monthly installments, contingent on the employees' continued service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL1bGy7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BKPKM429.USD","CNTX","BK4112","LU2095319765.USD","BK4588","BK4007","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2533579969","title":"Press Release: Context Therapeutics Reports First Quarter 2025 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533579969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533579969?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:09","pubTimestamp":1746648540,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents of $89.4 million as of March 31, 2025. Company expects its cash and cash equivalents will continue to fund operations into 2027. PHILADELPHIA, May 07, 2025  -- Context Therapeutics Inc.  , a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2025, and reported on recent and upcoming business highlights.-- In May 2025, announced Context board member, Dr. Karen Smith, to serve as. Interim Chief Medical Officer in connection with Dr. Claudio Dansky. -- In April 2025, presented preclinical and translational data for CT-95, a. MSLN targeting T cell engager, at the American Association for Cancer. trial evaluating CT-95 in patients with MSLN-expressing advanced solid. tumors, including ovarian, pancreatic, lung, and mesothelioma cancers.-- In January 2025, announced the first patient dosed in our Phase 1 trial. evaluating CTIM-76 in pat","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","LENZ"],"gpt_icon":0},{"id":"2533609942","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2533609942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533609942?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:00","pubTimestamp":1746612000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Prcs Mtls                                 3Q       .55    4:05 PM. ·Alpha and Omega                                  3Q      (.17)   4:01 PM. ·Ares Cmm. Rl Est                                 1Q       .00    6:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSY","BDTX","CPK","TKNO","TECH","AIRG","BRKR","AOSL","ADNT","CSGS","BLMN","BBSI","ACRE","BLZE","ALTG","BV","APA","AMRK","ASLE","BLBD","BLTE","BWA","CMTG","DFH","CIVI","CNTX","CVNA","EPC","DAY","DHX","CING","CRNC","BAND","CLRB","AVDX","CW","AVDL","GOLF","DIN","CXW","BYND","BTMD","CLF","CPRX","AXON","CTRI","RNAC","CF","AVA"],"gpt_icon":1},{"id":"2533755029","title":"Press Release: Context Therapeutics Announces Chief Medical Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2533755029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533755029?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:05","pubTimestamp":1746475500,"startTime":"0","endTime":"0","summary":"Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer. Dr. Smith has served on Context's Board since 2024 and is a biopharmaceutical thought leader with over 20 years of experience bringing drugs into the clinic and through commercialization. She was previously Global Head of Research & Development and Chief Medical Officer of Jazz Pharmaceuticals and has also held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb.\"As we take the next steps in advancing our pipeline, I am delighted to have Karen's support and leadership. Karen's experience in drug development will make her guidance invaluable through this transition,\" said Martin Lehr, CEO of Context. \"I am grateful to Claudio for his contributions to Context.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4007","BK4139","BK4232","CNTX","LENZ","BK4022"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}